文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

丹麦全国队列:生物制剂治疗IBD与IRD患者的结核病风险

Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study.
PubMed 文献 · Clin Microbiol Infect · 2025-06-21

该丹麦全国回顾性队列研究纳入1994-2018年IBD或IRD患者,比较生物制剂治疗与未治疗者的结核病发病率。IGRA阳性及出生在中/高结核发病率国家者风险显著更高。

要点

  • 生物制剂治疗者结核病发病率约为未治疗者的3.2倍。
  • IGRA阳性者结核病风险显著高于阴性者(IRR 45.0)。
  • 出生在中/高结核发病率国家者风险高于低发病率国家出生者。

核心结论

  • IBD和IRD患者使用生物制剂时结核病风险升高,且与IGRA阳性和出生国家强烈相关。

研究设计与样本

  • 丹麦全国回顾性队列研究,纳入1994-2018年诊断的IBD或IRD成人和儿童患者。

主要发现

  • 生物制剂治疗者粗结核病发病率为39.3/10万人年(95%CI 29.4-52.4)。
  • 未治疗者粗结核病发病率为12.4/10万人年(95%CI 9.2-16.8)。
  • 生物制剂治疗 vs 未治疗的发病率比IRR为3.2(95%CI 2.0-4.9)。
  • IGRA阳性 vs 阴性的IRR为45.0(95%CI 12.0-168.2)。
  • 出生在中发病率国家 vs 低发病率国家的IRR为7.9(95%CI 3.3-18.9),高发病率国家 vs 低发病率国家为7.5(95%CI 2.9-19.1)。

临床怎么用

  • 对IBD和IRD患者启动生物制剂前应进行全面的基线结核风险评估。
  • 结合IGRA结果和出生国家分层识别高风险患者,并开展患者教育。
  • 考虑个性化随访以指导该人群的结核病预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This nationwide retrospective cohort study estimates tuberculosis (TB) disease risk in adults and children with inflammatory bowel disease (IBD) and inflammatory rheumatic disease (IRD) treated with immunosuppressive biologics in Denmark, including temporal trends and risk stratification by TB infection status and country of birth. METHODS: Patients diagnosed with IBD or IRD from 1994 to 2018 were identified using the Danish National Patient Registry. Treatments with biologics and diagnoses of TB disease were determined through International Classification of Diseases, 10th Revision codes and microbiological records. Patient demographics, interferon-gamma release assay (IGRA) results, and drug use data were collected from national databases. Poisson regression was used to calculate TB incidence rates (IRs) and assess associations with biologic treatment, IGRA status, country of birth, age, and sex. RESULTS: During 553 551 person-years of follow-up, 117 patients with TB disease were identified, with 71 cases occurring in biologic-naïve patients and 46 in biologic-treated individuals. The crude IR was 39.3 of 100 000 person-years (95% CI, 29.4-52.4) for biologic-treated individuals, compared with 12.4 of 100 000 person-years (95% CI, 9.2-16.8) for naive patients, yielding an IR ratio (IRR) of 3.2 (95% CI, 2.0-4.9). The TB risk was higher in IGRA-positive patients (vs. negative, IRR 45.0, 95% CI, 12.0-168.2) and those born in intermediate (vs. low-incidence country, IRR 7.9, 95% CI, 3.3-18.9) or high TB incidence countries (vs. low-incidence country, IRR 7.5, 95% CI, 2.9-19.1). DISCUSSION: The elevated risk of TB disease in patients with IRD and IBD treated with biologics is strongly associated with IGRA positivity and country of birth. These findings highlight the importance of comprehensive baseline TB risk assessment and patient education in combination with personalized follow-up to guide preventive strategies in this population.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Kraef C, Østergaard AA, Lillebaek T, et al. Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study. Clin Microbiol Infect. 2025. PMID: 40550359. doi:10.1016/j.cmi.2025.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。